May 8 (Reuters) - Italian medical diagnostics company DiaSorin DIAS.MI said on Friday its net profit fell 28% to 38 million euros ($45 million) in the first quarter of 2026, impacted by "a weak flu season."

The company confirmed its 2026 guidance, albeit specifying it does not account for potential negative impacts related to a prolonged military conflict in the Middle East. In March, DiaSorin flagged the risks coming from logistical and distribution challenges in the Asia-Pacific region, and potential inflationary effects on its costs and supply chain.

First-quarter revenue growth in immunodiagnostics was negatively impacted by several one-off events, the company said in a statement, while adding it expected these to subside starting from the next period.

• Adjusted core earnings (EBITDA) fell 16% to 90 million euros in the first quarter

• First-quarter revenue stood at 287 million euros, with a negative foreign exchange (FX) impact of 17 millions

• For 2026, it expects an adjusted EBITDA margin in the range of 32%-33% and a yearly revenue growth between 5% and 6%

• "As of today, no specific forecasts can be provided," the company said regarding a potential guidance update in light of negative macroeconomic impacts

($1 = 0.8493 euros)